Stockscreener 앱 받기
1.45
3.97%
-0.06
시간 외 거래:
1.45
전일 마감가:
$1.51
열려 있는:
$1.48
하루 거래량:
1.50M
Relative Volume:
0.46
시가총액:
$409.76M
수익:
$53.43M
순이익/손실:
$-52.49M
주가수익비율:
-4.0401
EPS:
-0.3589
순현금흐름:
$-58.29M
1주 성능:
-19.44%
1개월 성능:
-9.94%
6개월 성능:
+18.85%
1년 성능:
+101.39%
1일 변동 폭
$1.44
$1.51
1주일 범위
$1.44
$1.86
52주 변동 폭
$0.46
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
명칭
Invivyd Inc
전화
(781) 819-0080
주소
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.45 | 426.72M | 53.43M | -52.49M | -58.29M | -0.3589 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-22 | 개시 | BTIG Research | Buy |
| 2025-11-25 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-10-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-26 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 개시 | H.C. Wainwright | Buy |
모두보기
Invivyd Inc 주식(IVVD)의 최신 뉴스
Inflation Data: Is Invivyd Inc exposed to currency risksWeekly Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Invivyd (IVVD) Q4 2025 Earnings Call Transcript - AOL.com
FY2027 Earnings Estimate for Invivyd Issued By HC Wainwright - MarketBeat
Invivyd Earnings Call Highlights Pivotal Trial Momentum - The Globe and Mail
Invivyd (NASDAQ:IVVD) Stock Price Up 6.3%Still a Buy? - MarketBeat
Invivyd appoints Michael Mina as chief medical officer - Investing.com Nigeria
Invivyd, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:IVVD) 2026-03-08 - Seeking Alpha
Invivyd, Inc. (NASDAQ:IVVD) Q4 2025 Earnings Call Transcript - Insider Monkey
Invivyd, Inc. (NASDAQ:IVVD) Receives Average Rating of "Hold" from Analysts - MarketBeat
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances By Investing.com - Investing.com Canada
Invivyd earnings beat by $0.11, revenue topped estimates - Investing.com Australia
Invivyd Q4 Earnings Call Highlights - MarketBeat
Michael Mina Appointed Chief Medical Officer at Invivyd - geneonline.com
Invivyd appoints Michael Mina as chief medical officer By Investing.com - Investing.com Australia
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances - Investing.com Nigeria
Invivyd Names Michael Mina Chief Medical Officer - Contract Pharma
Invivyd, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Invivyd Appoints Michael Mina, M.D., Ph.D. as Chief Medical Officer - citybiz
Earnings call transcript: Invivyd Q4 2025 shows robust growth and strategic expansion - Investing.com
Invivyd Advances VYD2311 With Key Phase 3 Alignments - TipRanks
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - The Globe and Mail
Invivyd 2025 10-K: Revenue $53.4M, Net Loss $52.5M - TradingView
Invivyd FY revenue rises; operating expenses cut sharply - TradingView
Michael Mina named chief medical officer, Invivyd, Inc. announces - Traders Union
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - The Manila Times
COVID testing voice Michael Mina now steering antibody drug effort - Stock Titan
Invivyd's Fourth Quarter 2025: Market Achievements Reflected in Valuation, Uneven Pipeline Risk - Bitget
An Overview of Invivyd's Earnings - Benzinga
Invivyd, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Invivyd (IVVD) to Release Earnings on Thursday - MarketBeat
Invivyd Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - The Manila Times
Invivyd (IVVD): Post-Data Plunge, Cash Runway And Next Catalysts For US Traders - AD HOC NEWS
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
IVVD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
New Invivyd staff get options on 192,000 shares at $1.69 each - Stock Titan
Invivyd (NASDAQ:IVVD) Earns "Buy" Rating from BTIG Research - MarketBeat
Analysts Offer Insights on Healthcare Companies: US Physical Therapy (USPH) and Invivyd (IVVD) - The Globe and Mail
New study maps COVID protection to antibody levels, not variants - Stock Titan
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies - The Globe and Mail
Aug Breakouts: Is Eaton Vance Senior Income Trust gaining market share2025 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
Lobbying Update: $20,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd (IVVD) CHRO Green sells $63k in stock after option exercise - Investing.com India
Invivyd (IVVD) CFO Duke sells shares worth $63,350 - Investing.com UK
Invivyd CSO Allen sells shares worth $58,600 By Investing.com - Investing.com Nigeria
Invivyd CSO Allen sells shares worth $58,600 - Investing.com South Africa
Invivyd Inc (IVVD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):